Overview
Autosomal dominant central core disease (ADCCD) is a rare genetic disorder characterized by muscle weakness and myopathy, primarily affecting skeletal muscles. This condition is caused by mutations in genes encoding proteins crucial for muscle fiber integrity and function, such as RAPSN or KBTBD10. Due to its rarity and genetic complexity, diagnosing and managing ADCCD presents unique challenges, particularly in terms of genetic linkage studies, differential diagnosis, and family screening. Understanding the epidemiology, diagnostic criteria, and management strategies is essential for clinicians to provide effective care and genetic counseling to affected families.
Epidemiology
The epidemiology of autosomal dominant central core disease (ADCCD) underscores the difficulties inherent in studying rare genetic disorders. Computer simulations highlight that detecting linkage for a dominant disease allele, such as those implicated in ADCCD, requires substantial sample sizes. For instance, achieving sufficient statistical power to identify linkage in only 25% of families necessitates enrolling approximately 380 families, given an alpha level of 0.25 [PMID:8362931]. This underscores the logistical and financial challenges faced in genetic research, particularly when dealing with small nuclear families or isolated cases. Consequently, collaborative efforts across multiple centers become crucial for enhancing the power of genetic studies and improving our understanding of disease prevalence and inheritance patterns. In clinical practice, these challenges translate into the need for extensive pedigree analysis and international consortia to pool data effectively.
Diagnosis
Diagnosing autosomal dominant central core disease (ADCCD) involves a multifaceted approach, emphasizing the importance of comprehensive genetic and clinical evaluations. Achieving robust linkage analysis, critical for confirming genetic diagnoses, often requires large collaborative efforts due to the low proportion of linked families in the population [PMID:8362931]. Clinicians must rely on detailed family histories, muscle biopsy findings, and genetic testing to identify characteristic features such as central cores on histological examination. These cores, along with clinical symptoms like muscle weakness and myalgias, are key indicators but may overlap with other myopathies, necessitating careful differential diagnosis. Effective diagnosis often hinges on integrating clinical presentation with genetic evidence, which can be enhanced through multidisciplinary teams and access to extensive genetic databases.
Clinical Presentation
The clinical presentation of ADCCD typically includes progressive muscle weakness, often affecting the proximal muscles more severely. Patients may also experience myalgias, exercise intolerance, and in some cases, respiratory muscle involvement. Early recognition can be challenging due to variable expressivity and penetrance of the disease. Muscle biopsy remains a cornerstone diagnostic tool, revealing characteristic histopathological features such as central cores, which are eosinophilic, rod-like structures within muscle fibers. Electromyography (EMG) may show myopathic changes, further supporting the diagnosis.
Genetic Testing
Genetic testing plays a pivotal role in confirming the diagnosis of ADCCD. Mutations in genes such as RAPSN and KBTBD10 have been implicated in this condition. Next-generation sequencing (NGS) panels and targeted gene sequencing can identify specific pathogenic variants. However, given the rarity of the disease, genetic counseling is essential to interpret results accurately and manage expectations regarding variable expressivity and incomplete penetrance. Collaboration with geneticists and genetic counselors ensures comprehensive support for both diagnostic confirmation and family planning considerations.
Differential Diagnosis
Differentiating autosomal dominant central core disease (ADCCD) from other myopathies requires meticulous clinical and genetic evaluation, often complicated by overlapping symptoms and genetic heterogeneity. Conditions such as nemaline myopathy, centronuclear myopathy, and other forms of congenital myopathies can present with similar clinical features, including muscle weakness and characteristic histopathological findings. Effective communication methods, including direct contact with relatives post proband consent, significantly enhance the identification of hereditary patterns and aid in narrowing down the differential diagnosis [PMID:39731470]. However, these practices vary widely across different jurisdictions, raising ethical considerations regarding privacy and consent. Clinicians must navigate these complexities carefully, ensuring that all family members are appropriately informed and involved in the diagnostic process while respecting legal and ethical guidelines.
Key Differential Conditions
Management
The management of autosomal dominant central core disease (ADCCD) focuses on symptomatic relief, supportive care, and proactive family screening to mitigate disease impact and facilitate informed reproductive decisions. Cascade genetic testing, particularly reverse cascade testing initiated from infant probands, is a critical strategy for identifying at-risk relatives [PMID:39731470]. This approach not only aids in early surveillance and intervention but also supports genetic counseling for reproductive planning. However, the uptake of such testing can be hindered by communication barriers and ethical concerns, necessitating tailored counseling approaches that address individual family dynamics and values.
Symptomatic Treatment
Symptomatic management in ADCCD often involves addressing muscle weakness and associated complications:
Family Screening and Counseling
Given the autosomal dominant inheritance pattern, cascade genetic testing is essential:
Recurrence Risk
The risk of recurrence for siblings of an affected child, especially when neither parent is affected, can be surprisingly high, potentially exceeding 10% and reaching over 25% if the carrier genotype exhibits high fitness [PMID:3978840]. This underscores the importance of comprehensive genetic counseling to accurately convey these risks and support families in making informed decisions regarding future pregnancies and family planning strategies.
Prognosis & Follow-up
The prognosis for individuals with autosomal dominant central core disease (ADCCD) varies widely based on the severity of symptoms and the specific genetic mutation involved. While some patients may experience relatively stable conditions with manageable symptoms, others might face progressive muscle weakness and respiratory complications. Recent studies suggest that early genetic testing in infants for adult-onset conditions, despite historical concerns about psychological impacts, can offer significant benefits in terms of long-term management and quality of life [PMID:39731470]. This highlights the need for longitudinal follow-up strategies that integrate clinical monitoring with psychological support to address the evolving needs of patients and their families.
Long-term Monitoring
Research Directions
Further research is needed to better understand the natural history of ADCCD and to develop targeted therapeutic interventions. Longitudinal studies tracking patients over decades can provide valuable insights into disease progression and response to various management strategies, ultimately informing more personalized care plans.
Key Recommendations
References
1 Uveges MK, Smith HS, Pereira S, Genetti C, McGuire AL, Beggs AH et al.. Family genetic risk communication and reverse cascade testing in the BabySeq project. Genetics in medicine : official journal of the American College of Medical Genetics 2025. link 2 Levinson DF. Power to detect linkage with heterogeneity in samples of small nuclear families. American journal of medical genetics 1993. link 3 Friedman JM. Genetic counseling for autosomal dominant diseases with a negative family history. Clinical genetics 1985. link